AU2019251148A1 - Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist - Google Patents
Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist Download PDFInfo
- Publication number
- AU2019251148A1 AU2019251148A1 AU2019251148A AU2019251148A AU2019251148A1 AU 2019251148 A1 AU2019251148 A1 AU 2019251148A1 AU 2019251148 A AU2019251148 A AU 2019251148A AU 2019251148 A AU2019251148 A AU 2019251148A AU 2019251148 A1 AU2019251148 A1 AU 2019251148A1
- Authority
- AU
- Australia
- Prior art keywords
- mmol
- alkyl
- methyl
- compound
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CNPCT/CN2018/082140 | 2018-04-08 | ||
| CN2018082140 | 2018-04-08 | ||
| PCT/CN2019/081785 WO2019196803A1 (en) | 2018-04-08 | 2019-04-08 | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2019251148A1 true AU2019251148A1 (en) | 2020-10-22 |
Family
ID=68163465
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019251148A Abandoned AU2019251148A1 (en) | 2018-04-08 | 2019-04-08 | Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11472811B2 (https=) |
| EP (1) | EP3774813A4 (https=) |
| JP (1) | JP2021520392A (https=) |
| KR (1) | KR20200140849A (https=) |
| CN (1) | CN112313234B (https=) |
| AU (1) | AU2019251148A1 (https=) |
| BR (1) | BR112020020078A2 (https=) |
| CA (1) | CA3095839A1 (https=) |
| EA (1) | EA202092036A1 (https=) |
| IL (1) | IL277744A (https=) |
| MX (1) | MX2020010618A (https=) |
| SG (1) | SG11202009706VA (https=) |
| TW (1) | TW202010500A (https=) |
| WO (1) | WO2019196803A1 (https=) |
| ZA (1) | ZA202005772B (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020010618A (es) | 2018-04-08 | 2020-11-12 | Beigene Ltd | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. |
| CA3177057A1 (en) * | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | Triazolone compounds |
| WO2021191376A1 (en) * | 2020-03-26 | 2021-09-30 | Astrazeneca Ab | Triazolone compounds |
| EP4214200A1 (en) | 2020-10-22 | 2023-07-26 | Nimmune Biopharma, Inc. | Lancl ligands |
| CN113773327B (zh) * | 2021-09-13 | 2022-07-15 | 八叶草健康产业研究院(厦门)有限公司 | 一种吡唑并嘧啶并三唑环类化合物的制备方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1283839T1 (https=) * | 2000-05-26 | 2005-08-31 | Schering Corp | |
| AU2002347055B2 (en) | 2001-10-08 | 2006-10-12 | F. Hoffmann-La Roche Ag | Substituted Triazolopyridine Compounds |
| US20030139427A1 (en) | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
| EP1745047B1 (en) | 2004-04-21 | 2010-03-24 | Schering Corporation | Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidine adenosine-a2a- receptor antagonists |
| CN103261202B (zh) * | 2010-09-24 | 2016-01-20 | 阿迪维纳斯疗法有限公司 | 作为腺苷受体拮抗剂的稠合三环化合物 |
| WO2012135084A1 (en) | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
| WO2017136375A1 (en) | 2016-02-05 | 2017-08-10 | Concert Pharmaceuticals, Inc. | Deuterated tozadenant |
| MX2020010618A (es) | 2018-04-08 | 2020-11-12 | Beigene Ltd | Derivados de pirazolotriazolopiriminina como antagonista del receptor a2a. |
| CN110742893B (zh) | 2018-07-23 | 2024-04-05 | 百济神州(北京)生物科技有限公司 | A2a受体拮抗剂治疗癌症的方法 |
-
2019
- 2019-04-08 MX MX2020010618A patent/MX2020010618A/es unknown
- 2019-04-08 CA CA3095839A patent/CA3095839A1/en active Pending
- 2019-04-08 KR KR1020207031434A patent/KR20200140849A/ko not_active Ceased
- 2019-04-08 AU AU2019251148A patent/AU2019251148A1/en not_active Abandoned
- 2019-04-08 EA EA202092036A patent/EA202092036A1/ru unknown
- 2019-04-08 WO PCT/CN2019/081785 patent/WO2019196803A1/en not_active Ceased
- 2019-04-08 TW TW108112189A patent/TW202010500A/zh unknown
- 2019-04-08 EP EP19785064.7A patent/EP3774813A4/en not_active Withdrawn
- 2019-04-08 SG SG11202009706VA patent/SG11202009706VA/en unknown
- 2019-04-08 JP JP2020554834A patent/JP2021520392A/ja not_active Withdrawn
- 2019-04-08 BR BR112020020078-6A patent/BR112020020078A2/pt not_active IP Right Cessation
- 2019-04-08 CN CN201980024422.3A patent/CN112313234B/zh not_active Expired - Fee Related
- 2019-04-08 US US16/982,681 patent/US11472811B2/en active Active
-
2020
- 2020-09-17 ZA ZA2020/05772A patent/ZA202005772B/en unknown
- 2020-10-01 IL IL277744A patent/IL277744A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN112313234A (zh) | 2021-02-02 |
| EP3774813A1 (en) | 2021-02-17 |
| TW202010500A (zh) | 2020-03-16 |
| US20210198267A1 (en) | 2021-07-01 |
| IL277744A (en) | 2020-11-30 |
| WO2019196803A1 (en) | 2019-10-17 |
| MX2020010618A (es) | 2020-11-12 |
| SG11202009706VA (en) | 2020-10-29 |
| ZA202005772B (en) | 2022-01-26 |
| CA3095839A1 (en) | 2019-10-17 |
| KR20200140849A (ko) | 2020-12-16 |
| BR112020020078A2 (pt) | 2021-01-05 |
| US11472811B2 (en) | 2022-10-18 |
| EP3774813A4 (en) | 2021-11-17 |
| JP2021520392A (ja) | 2021-08-19 |
| EA202092036A1 (ru) | 2021-01-28 |
| CN112313234B (zh) | 2022-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019251148A1 (en) | Pyrazolotriazolopyrimidine derivatives as A2A receptor antagonist | |
| CN114585359B (zh) | 用于治疗pd-l1疾病的杂芳基联苯酰胺 | |
| WO2021058018A1 (en) | Inhibitors of kras g12c | |
| WO2021013083A1 (en) | Tricyclic compounds as hpk1 inhibitor and the use thereof | |
| WO2021032148A1 (en) | Aminopyrazine compounds as hpk1 inhibitor and the use thereof | |
| CA3228862A1 (en) | Pyrazolopyridinone compounds | |
| WO2021170046A1 (en) | Tyk-2 inhibitor | |
| TWI762534B (zh) | 作為ＰＩ３Ｋδ抑制劑的咪唑並[1,5-A]吡衍生物 | |
| WO2023098699A1 (en) | Compounds and their uses as cd38 inhibitors | |
| EP4499630A1 (en) | Bcl-xl inhibitors | |
| US20240300937A1 (en) | Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors | |
| CN110742893B (zh) | A2a受体拮抗剂治疗癌症的方法 | |
| EP4608826A1 (en) | Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors | |
| WO2022067462A1 (en) | Process for preparing inhibitors of kras g12c | |
| CN115667274A (zh) | 作为sting调节剂的杂环化合物 | |
| WO2020048409A1 (en) | 1,5-NAPHTHYRIDIN-4(1H)-ONE DERIVATIVES AS PI3Kbeta INHIBITORS | |
| HK40036174A (en) | Pyrazolotriazolopyrimidine derivatives as a2a receptor antagonist | |
| WO2024230803A1 (en) | Isoquinolinone derivatives and 4h-quinolizinone derivatives and pharmarceutical compositions thereof for the treatment of disease | |
| WO2024251187A1 (en) | Benzofuran derivatives as sik inhibitors and use thereof | |
| WO2024153233A1 (en) | Compounds and their uses as gpr17 antagonists | |
| WO2025078995A1 (en) | Substituted 6-(pyrimidin-4-yl)quinoline compounds as cyclin dependent kinase inhibitors | |
| WO2020233677A1 (en) | Process for preparing amide-substituted imidazo compounds |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1 | Application lapsed section 142(2)(a) - no request for examination in relevant period |